SPECTAforum 2014: Videos available for viewing
27 May 2014
The second edition of SPECTAforum met its objectives with representation of most of the stakeholders. With SPECTAcolor, the first platform, now rapidly reaching over 200 patients, SPECTA, an innovative approach to efficient access to molecular target-based clinical trials, has demonstrated international feasibility. Routes for stakeholders to join SPECTA are now being launched. Additional disease-oriented platforms are actively being developed and will be launched soon.
Related News
New European AI assistant to make patient experiences actionable for care and health systems
12 Nov 2026
First site activated in EORTC STARBURST-1, the research project on muscle-invasive bladder cancer
28 Oct 2026
EORTC at ESMO 2026: New findings and ongoing studies
27 Oct 2026
EORTC research presented at ESMO 2026
22 Oct 2026
EORTC Quality of Life Group at ISOQOL 2026
15 Oct 2026
Pink October 2026: Advancing breast cancer research, together
7 Oct 2026
EORTC presents new results in neuro-oncology at EANO
28 Sep 2026
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
